Vivace Therapeutics closed $35M Series D round

Vivace Therapeutics recently announced the successful completion of its Series D financing round, securing $40 million. The investment was led by RA Capital Management, with continued support from existing investors Canaan Partners and Cenova Capital. This new capital infusion is designated to propel the company's lead oncology program into clinical development.

Vivace Therapeutics is pioneering cancer treatments by targeting the Hippo-YAP/TEAD pathway, a critical signaling cascade implicated in tumor growth, metastasis, and treatment resistance. Their lead candidate, VT-01, is a first-in-class, orally bioavailable small molecule TEAD inhibitor. The company plans to utilize the Series D funds to advance VT-01 into Phase 1 clinical trials, initially focusing on patients with advanced solid tumors, including mesothelioma. This approach aims to address unmet medical needs in cancers driven by the dysregulation of the Hippo pathway.